News required to move price upwardsNow that short term credit facility concerns are behind us, at least until end of November, KNE needs to present some good news to the market in order to gains some momentum. Here are the one I see as short term priorities (ie.: before end of October/November);
1. News about the first Coactiv+ order from Progenacare shortly followed by one about the first product delivery;
2. News about the start of the DispersinB phase 1 trial with DoD;
3. News on the DispersinB clinical trial for acne with the UofMiami.
All of the above needs to be announced as soon as possible in order to meet previously published expectations by the company.
P.S.I'm still puzzled by the fact that Progenacare (and Salud Pharma) are not posting their deal with Kane about the Coactiv+ product and don't even show the product on their respective website.
GLTA